Molecular dynamics simulations exploring drug resistance in HIV-1 proteases

Chinese Science Bulletin

Volumn 55, Issue 24, 2010, Pages 2677-2683

  Gu, Hui ^a   Chen, Hai Feng ^a   Wei, Dong Qing ^a   Wang, Jing Fang ^a,b  

^a SHANGHAI JIAO TONG UNIVERSITY   (China)

^b Shanghai Centre for Bioinformation Technology   (China)

Author keywords

drug resistance; HIV 1 protease; hydrogen bonds; hydrophobic interactions; molecular dynamics simulations

Indexed keywords

CERCOPITHECINE HERPESVIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS; HUMAN IMMUNODEFICIENCY VIRUS 1;

EID: 77955836275     PISSN: 10016538     EISSN: 18619541     Source Type: Journal    
DOI: 10.1007/s11434-010-3257-6     Document Type: Article

References (28)

1. UNAIDS. Annual Report 2009, http://data. unaids. org/pub/Report/2010/2009_annual_report_en. pdf.
2. Caride E, Hertogs K, Larder B, et al. Genotypic and phenotypic evidence of different drug-resistance mutation patterns between B and non-B subtype isolates of human immunodeficiency virus type 1 found in Brazilian patients failing HAART. Virus Genes, 2001, 23: 193-202.
3. Foulkes-Murzycki J E, Scott W R, Schiffer C A. Hydrophobic sliding: A possible mechanism for drug resistance in human immunodeficiency virus type 1 protease. Structure, 2007, 15: 225-233.
4. Abramowitz N, Schechter I, Berger A. On the size of the active site in protease. II. Carboxypeptidase-A. Biochem Biophys Res Commun, 1967, 29: 862-867.
5. Schechter I, Berger A. On the size of the active site in protease. I. Papain. Biochem Biophys Res Commun, 1967, 27: 157-162.
6. DeGruttola V, Dix L, Aquila D R, et al. The relation between baseline HIV drug resistance and response to antiretroviral therapy: Re-analysis of retrospective and prospective studies using a standardized data analysis plan. Antivir Ther, 2000, 5: 41-48.
7. Ledergerber B, Egger M, Erard V, et al. AIDS-related opportunistic illnesses occurring after initiation of potent antiretroviral therapy: The Swiss HIV cohort study. Jama, 1999, 82: 2220-2226.
8. Sanches M, Krauchenco S, Martins N H, et al. Structural characterization of B and non-B subtypes of HIV-protease: Insights into the natural susceptibility to drug resistance development. J Mol Biol, 2007, 369: 1029-1040.
9. Case D A, Pearlman D A, Caldwell J W, et al. AMBER 8. San Francisco: University of California, 2004.
10. Kollman P A, Cornell W D, Chipot C, et al. The development/application of "minimalist"organic/biochemical molecular mechanic force field using a combination of ab initio calculations and experimental data. Comp Simulat Biolog Syst, 1997, 3: 83-96.
11. Jorgensen W L, Madura J D, Impey R W, et al. Comparison of simple potential functions for simulating liquid water. J Chem Phys, 1983, 79: 926-935.
12. Wang J, Wolf R M, Caldwell J W, et al. Development and testing of a general amber force field. J Comput Chem, 2004, 25: 1157-1174.
13. Rychaert J P, Berendsen H J C. Numerical integration of Cartesian equations of motion of a system with constraints: Molecular dynamics of n-alkanes. Comput Phys, 1977, 23: 327-341.
14. Darden T, Pedersen L. Particle mesh Ewald: An N-log(N) method for Ewald sums in large systems. J Chem Phys, 1993, 98: 10089-10092.
15. Wang J F, Wei D Q, Li L, et al. 3D structure modeling of cytochrome P450 2C19 and its implication for personalized drug design. Biochem Biophys Res Commun, 2007, 355: 513-519.
16. Wang J F, Wei D Q, Lin Y, et al. Insights from modeling the 3D structure of NAD(P)H-dependent D-xylose reductase of Pichia stipitis and its binding interactions with NAD and NADP. Biochem Biophys Res Commun, 2007, 359: 323-329.
17. Wang J F, Wei D Q, Chen C, et al. Molecular modeling of two CYP2C19 SNPs and its implications for personalized drug design. Protein Pept Lett, 2008, 15: 27-32.
18. Wang J F, Wei D Q, Chou K C. Pharmacogenomics and personalized use of drugs. Curr Top Med Chem, 2008, 8: 1573-1579.
19. Wang J F, Wei D Q, Chou K C. Drug candidates from traditional Chinese medicine. Curr Top Med Chem, 2008, 8: 1656-1665.
20. Wang J F, Zhang C C, Chou K C, et al. Structure of cytochrome P450s and personalized drug. Curr Med Chem, 2009, 16: 232-244.
21. Wang J F, Gong K, Wei D Q, et al. Molecular dynamics studies on the interactions of PTP1B with inhibitors: From the first phosphate-binding site to the second one. Protein Eng Des Sel, 2009, 22: 349-355.
22. Wang J F, Wei D Q, Chou K C. Insights from investigating the interactions of adamantane-based drugs with the M2 proton channel from the H1N1 swine virus. Biochem Biophys Res Commun, 2009, 388: 413-417.
23. Wang J F, Chou K C. Insights into the molecular switch mechanism of human Rab5a from molecular dynamics simulations. Biochem Biophys Res Commun, 2009, 390: 608-612.
24. Wallace A C, Laskowski R A, Thornton J M. LIGPLOT: a program to generate schematic diagrams of protein-ligand interactions. Protein Eng, 1995, 8: 127-134.
25. Hansch C. Quantitative structure-activity relationships and the unnamed science. Acc Chem Res, 1993, 26: 147-153.
26. Hansch C, Hoekman D, Gao H. Comparative QSAR: Toward a deeper understanding of chemicobiological interactions. Chem Rev, 1996, 96: 1045-1076.
27. Physicians Desk Reference. Montvale, USA: Medical Ergonomics Data Production Company, 1995.
28. Hong L, Zheng X C, Hartsuck J A, et al. Crystal structure of an in vivo HIV-1 protease mutant in complex with saquinavir: Insights into the mechanism of drug resistance. Protein Sci, 2000, 9: 1898-1904.